

Time to Endovascular Treatment and Outcomes in the DAWN Trial

Purpose: Because of DAWN trial findings that with clinical-core mismatch (CCM) there may be benefits with thrombectomy at 6-24 hours, this trial evaluated time to randomization in the DAWN trial and outcomes.

Trial Design: Multivariate logistic regression used to evaluate interaction between time last seen well until puncture for thrombectomy.

Primary Endpoints: Outcomes at 90 days (measured by odds ratio – cOR and absolute risk difference – ARD for mRS 0-2) at different treatment time points

Treatment Benefit @ 90 days	Thrombectomy given at 8 hours	12 hours	16 hours	20 hours	24 hours
cOR	6.8	9.4	13	17.8	24.6
ARD for mRS 0-2	24.4%	35.1%	37.2%	36.5%	35.5%

Selected clinical core mismatch patients demonstrated benefit from thrombectomy up to 24 hours, although the chance for good outcomes decreased over time. Functional independence decreases for every hour that treatment is delayed.